Gilead in pact for anti-inflammatory drugs in a deal worth up to $1.7B
Gilead Sciences (NASDAQ:GILD) and Danish pharmaceutical company LEO Pharma on Saturday announced an agreement worth up to ...
pharmaphorum4d
LEO closes on first approval for chronic hand eczema drug
Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.
FiercePharma23d
Sanofi and Regeneron's Dupixent, Leo Pharma's Anzupgo could help close treatment gap in chronic hand eczema: GlobalData
Leo Pharma, meanwhile, announced this fall that it had submitted its delgocitinib cream for FDA approval as a treatment for adults with moderate to severe CHE for whom topical corticosteroids ...
Hosted on MSN1mon
LEO Pharma’s eczema cream gains MHRA marketing authorisation
LEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus kinase (JAK) inhibitor, Anzupgo (delgocitinib ...
pharmaphorum8d
LEO Pharma teams up with Wearifi for dermatology research wearable
LEO Pharma is developing a wearable device based on miniature sensors and plans to assess its clinical potential in dermatology drug development. The pharmaceutical company’s Boston-based R&D ...
PharmiWeb3d
Experienced Industry Leader Dr. Joerg Moeller Appointed as Chief Executive Officer of Antag Therapeutics
Antag Therapeutics (“Antag” or “the company”), a biopharmaceutical company pioneering novel treatments for obesity, today announced the appointment of Joerg Moeller, MD, PhD, as Chief Executive ...
Pharmabiz1mon
UK MHRA grants marketing authorization to Leo Pharma’s delgocitinib to treat adult patients with moderate to severe chronic hand eczema
The new marketing authorisation was granted in 59 days on 29 November 2024 to Leo Pharma AS under the International Recognition Procedure (IRP) Route B. Anzupgo contains the active substance ...